Nov. 12, 2020—Vanderbilt contributes molecular imaging data of kidney to the Human BioMolecular Atlas Program, a consortium of 18 diverse collaborative research teams across the United States and Europe.
Nov. 12, 2020—Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.
Nov. 10, 2020—Erin Calipari, assistant professor of pharmacology and of psychiatry and behavioral sciences, discusses the COVID-19 pandemic's impact on those struggling with opioid addiction.
Nov. 9, 2020—Yi Ren, assistant professor of biochemistry, has contributed to research on the function and impact of the SARS-CoV-2 protein on immune signaling protein in host cells. This understanding may lead to the development of immune-enhancing therapeutics.
Discovery Science Emerging Scholars Lecture: ‘Investigating the molecular regulation and function of death signaling complexes’ Nov. 19
Nov. 8, 2020—Cornelius Taabazuing, a postdoctoral fellow at the Memorial Sloan-Kettering Cancer Center, will present “Investigating the molecular regulation and function of death signaling complexes.” The Discovery Science Emerging Scholars Lecture is scheduled for Thursday, Nov. 19, at 9:30 a.m. via Zoom.
Nov. 6, 2020—Assistant Professor of Biochemistry Yi Ren and her team have made several discoveries to illuminate the mechanisms of key host-pathogen interactions involving viruses, with implications for gaining a better understanding of SARS-CoV-2, the virus that causes COVID-19.
Nancy Carrasco’s pioneering public health work recognized with National Academy of Medicine election
Nov. 4, 2020—Nancy Carrasco, professor and chair of the Department of Molecular Physiology and Biophysics and the Joe C. Davis Chair of Biomedical Science, receives one of the highest honors in health and medicine.
Spontaneous release of neurotransmitters in the brain identified as a culprit of developmental disorders in infants and children
Nov. 3, 2020—Vanderbilt researchers discover how a group of neurodevelopmental disorders ranging in severity are caused in infants and children, opening new avenues for therapeutics.
Jerri Rook is awarded the Alzheimer’s Drug Discovery Foundation’s prestigious Melvin R. Goodes prize
Nov. 2, 2020—Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research.
Oct. 29, 2020—Histamine — commonly associated with allergies — also has a signaling role in the brain’s reward center and may offer a novel target for treating addiction.
Vanderbilt University anti-inflammatory therapy licensed to Amytrx is now in clinical trials for eczema treatment
Oct. 27, 2020—Jacek Hawiger’s anti-inflammatory peptide therapy, licensed by Amytrx and now in clinical trials, has the potential to safely and effectively treat a multitude of inflammatory and metabolic diseases.
Oct. 27, 2020—Vanderbilt researchers—including Charles Sanders, associate dean for research and professor of biochemistry, and graduate student Justin Marinko—have illuminated the cause of Charcot-Marie-Tooth disease, putting them on the road to developing therapeutic approaches for the disease that affects one in 2,500 people.